Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

Inclusion Criteria

• •1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• •2. Age ≥ 18 years at the time of consent.
• •3. Subjects must meet one of the following criteria:
• •* Subjects suspected or diagnosed with recurrent, locally advanced or metastatic cancer:
• •* Bladder: Urothelial Carcinoma (UC)
• •* Kidney: Clear Cell Renal Cell Carcinoma (ccRCC)
• •* Subjects suspected or diagnosed with recurrent or metastatic cancer:
• •* Colon and Rectum: Microsatellite instability-high (MSI-H)/deficient mismatch repair (dMMR) Colorectal Cancer (CRC)
• •* Head and Neck: Squamous Cell Carcinoma (HNSCC), excluding nasopharyngeal and salivary gland cancers
• •* Liver: Hepatocellular Carcinoma
• •* Lung: Non-small cell lung cancer (NSCLC)
• •* Skin: Cutaneous Melanoma, excluding Uveal Melanoma
• •* Uterus: endometrial cancer
• •* Subjects suspected or diagnosed with one of the following cancer types eligible for pure ICI neoadjuvant therapy:
• •o Skin: Cutaneous Melanoma, Stage III
• •* Subjects suspected or diagnosed with:
• •* Any solid tumor type that is eligible for pure ICI therapy in the neoadjuvant or advanced/metastatic setting
• •* Any metastatic solid tumor with high TMB, MSI-High or dMMR and are being considered for treatment with ICI therapy.
• •* Any recurrent or metastatic patient with a solid tumor that the clinician plans to treat with ICI therapy.
• •4. Subjects must be clinically able, at investigator discretion, to undergo a biopsy procedure
• •5. Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.